3 results about "Xeno free" patented technology

This invention discloses a xenogeneic-free culture method for hiPSCs and its quality monitoring method. The xenogeneic-free culture method includes the following steps: hiPSC cells are seeded into the wells of a culture plate coated with VTN-N matrix gel, and cultured for the first stage using E8 complete medium containing 5-15 µM Y-27632. After 20-30 h of culture, the medium is replaced with conventional E8 complete medium without Y-27632 for the second stage of culture, until the cell confluence reaches 60%-80%. This xenogeneic-free culture method ensures efficient cell expansion under conditions with clearly defined chemical composition. This method further optimizes the seeding density and culture period of hiPSCs, controls cell passage at 60%-80% confluence, and significantly reduces the risk of spontaneous differentiation by limiting the maximum culture time and upper limit of confluence.

Disclosed herein are methods for utilizing and forming suspension cultures of pluripotent stem cells (PSCs), and differentiated cells, spheroids, and organoids derived from PSCs (e.g., with industrial efficiency and / or scalability), as well as compositions comprising them. These methods can be carried out in suspension culture without the use of a basement membrane matrix during the maintenance and expansion of PSCs, and during the differentiation of PSCs into differentiated cells and organoids, such as endoderm (DE), hindgut spheroids (HGS), and intestinal organoids (IO). In some embodiments, the methods may be xenofree and may be carried out in accordance with Good Manufacturing Practices (GMP). Also disclosed herein are methods for controlling the polarity of epithelial cells in IOs, such that the apical layer is oriented outside the organoid, or alternatively inside the organoid. The use of methods and compositions for transplantation and therapeutic purposes is also disclosed.

This invention relates to a method for inducing midbrain dopaminergic neurons and the neurons obtained therefrom. The solution provided by this invention provides a scaffold-based three-dimensional differentiation system for guiding the differentiation of human induced pluripotent stem cells into midbrain dopaminergic neurons. This system, as a scalable platform without xenogeneic component compatibility, has advantages in the efficient production of midbrain dopaminergic neurons and has wide applications in disease modeling, drug screening, and regenerative medicine.